Effects of bimatoprost topical: A Synthesis of Findings from 24 Studies

  1. Home
  2. Effects of bimatoprost topical
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of bimatoprost topical: A Synthesis of Findings from 24 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of bimatoprost topical: A Synthesis of Findings from 24 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Bimatoprost, a commonly used prostaglandin analogue (PGA) for glaucoma treatment, has been found to have various effects on the eye and its surrounding tissues. Studies have shown that bimatoprost can effectively lower intraocular pressure (IOP), a major factor in glaucoma development. 2 12 Additionally, bimatoprost has been investigated for its potential in treating hair loss, particularly alopecia areata, with some promising results. 16 However, research also highlights potential side effects associated with bimatoprost, including periorbital fat atrophy, a condition that could affect the appearance of the eye area. 1 10 Furthermore, concerns have been raised regarding the long-term safety and tolerability of bimatoprost, prompting investigations into the potential for ocular surface alterations. 11 18 To address the challenges of topical drug delivery and optimize treatment efficacy, researchers are exploring innovative sustained-release drug delivery systems for glaucoma management. 23

Benefits and Risks

Benefits Summary

Bimatoprost has demonstrated efficacy in lowering intraocular pressure (IOP), a key factor in the management of glaucoma. 2 12 It has also shown potential in stimulating hair growth, potentially offering a treatment option for hair loss conditions like alopecia areata. 16

Risks Summary

Bimatoprost can cause periorbital fat atrophy, which may alter the appearance of the eye area. 1 10 It can also lead to other side effects, including ocular inflammation, hyperemia, and cystoid macular edema. 22 9 While its effectiveness for glaucoma is established, long-term safety and tolerability require further investigation. 18

Comparison of Studies

Commonalities

The studies highlight bimatoprost's efficacy in lowering IOP and its potential role in treating hair loss. 2 12 16 They also consistently mention periorbital fat atrophy as a potential side effect. 1 10

Differences

The studies differ in their focus, methodology, and the specific types of bimatoprost formulations investigated. Some studies focus on the efficacy of bimatoprost in treating glaucoma, while others explore its potential in hair loss treatment. 2 12 16 The study design, including patient populations and the duration of treatment, also varies across these studies. 2 12 16

Consistency and Contradictions

While the studies generally agree on bimatoprost's efficacy in lowering IOP and its potential for periorbital fat atrophy, the severity and frequency of side effects can vary depending on the formulation and individual patient factors. 1 10 It is crucial to understand that individual responses to bimatoprost can differ, and further research is needed to better characterize these variations.

Implications for Everyday Life

If you are considering bimatoprost for glaucoma treatment or hair loss, it's essential to discuss the potential benefits and risks with your doctor. 1 They can advise you on the appropriate formulation and dosage, and monitor your progress closely for any side effects.

Limitations of Current Research

The studies reviewed here offer valuable insights into bimatoprost's effects, but they also have limitations. Some studies are limited by their sample size, while others focus on specific aspects of bimatoprost's action without providing a comprehensive overview. Further research is necessary to address these limitations and provide a more complete picture of bimatoprost's long-term effects.

Future Research Directions

Future research should investigate the long-term safety and tolerability of bimatoprost, including its effects on the ocular surface, periorbital fat, and overall eye health. 11 18 Studies should also explore individualized responses to bimatoprost, identifying factors that might influence the development of side effects. Additionally, research into innovative drug delivery systems, such as sustained-release implants, could improve patient compliance and minimize the risk of side effects. 23

Conclusion

Bimatoprost is a potent medication with both benefits and risks. Its efficacy in lowering IOP makes it a valuable tool for glaucoma management, but its potential for periorbital fat atrophy and other side effects should be carefully considered. 1 10 Open communication with your healthcare provider is crucial to ensure informed decision-making and safe and effective treatment. 1 10

Literature analysis of 24 papers
Positive Content
20
Neutral Content
2
Negative Content
2
Article Type
3
0
0
4
23
3.

Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial.

Author: ZakyMohamed S, HashemOsama A, MahfouzSara M, ElsaieMohamed L

Eyebrow enhancement
Improved eyebrow appearance

Both 0.01% and 0.03% bimatoprost and 2% minoxidil gel formulations are effective in improving eyebrow growth in individuals with eyebrow hypotrichosis. However, bimatoprost at a concentration of 0.03% may produce a more favorable response.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Trends in development and quality assessment of pharmaceutical formulations - F2α analogues in the glaucoma treatment.

Author: Asendrych-WicikKatarzyna, ZarczukJakub, WalaszekKatarzyna, CiachTomasz, Markowicz-PiaseckaMagdalena

Glaucoma treatment

This review discusses analytical methods for determining the content and related substances in PGF2α analogues used for glaucoma treatment. The instability of these analogues in aqueous solution and the phenomenon of isomerism are highlighted as important factors influencing the development of stability-indicating analytical methods.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Enhanced Uptake and Retention of 0.03% Bimatoprost, 0.5% 5-Fluorouracil, and 5% Minoxidil After 1,550-nm or 1,927-nm Nonablative Laser Pretreatment.

Author: WangJordan V, FriedmanPaul M, AgronSamantha, KondaAdarsh, ParkerCatherine, GeronemusRoy G

Enhanced topical uptake
Improved treatment efficacy

This study examines the increasing popularity of laser pretreatment with cosmeceutical topicals and the potential to optimize treatment protocols by quantifying the permeation of medical topicals.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
CommentA short article/note that provides an opinion/perspective/interpretation on a published paper/topic.

Language : English

10.

Do Prostaglandin Analogue Lash Lengtheners Cause Eyelid Fat and Volume Loss?

Author: JamisonAaron, OkaforLinda, UllrichKatja, SchiedlerVivian, MalhotraRaman

Eyelash lengthening
Periorbital volume loss

Prostaglandin analogues (PGAs) are commonly used to treat glaucoma and are also marketed as eyelash-lengthening serums. Periorbital volume loss is a known side effect of topical PGAs used for glaucoma, but this has not been reported as a potential side effect of lash-lengthening serums containing PGAs. This raises concerns about the potential for periorbital volume loss associated with these popular cosmetic products.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

11.

<i>In Vitro</i> Corneal and Conjunctival Wound-Healing Assays as a Tool for Antiglaucoma Prostaglandin Formulation Characterization.

Author: LiangHong, BaudouinChristophe, DaullPhilippe, GarrigueJean-Sébastien, Brignole-BaudouinFrançoise

Improved healing
Delayed healing

This study found that benzalkonium chloride (BAK)-containing antiglaucoma therapies delayed corneal healing in a dose-dependent manner. The presence of BAK, even in low concentrations, significantly slowed corneal epithelial cell migration and proliferation. BAK-free antiglaucoma therapies maintained normal corneal healing.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.

Author: OddoneFrancesco, KirwanJames, Lopez-LopezFernando, ZiminaMarina, FassariClaudia, HollóGábor,

IOP reduction

This study sub-analyzed data from the VISIONARY study to evaluate the effectiveness of a preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (PF tafluprost/timolol FC) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) who were sub-optimally controlled on prostaglandin analogue (PGA) or beta-blocker monotherapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Shortening of interpupillary distance after topical prostaglandin analog eye drop application in an ophthalmic surgeon: A case report.

Author: SanoIchiya, TakahashiHidenori, HaraTakeshi, KawashimaHidetoshi, MayamaChihiro

Binocular vision changes
IPD shortening

This case report describes a patient who experienced interpupillary distance (IPD) shortening after instillation of topical prostaglandin analog (PGA) eye drops. The IPD partially recovered upon discontinuation of the medication. This suggests that PGA eye drops may have effects on binocular vision that require further investigation.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

17.

Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).

Author: BacharachJason, TathamAndrew, FergusonGloria, BelalcázarSandra, ThiemeHagen, GoodkinMargot L, ChenMichelle Y, GuoQiang, LiuJeen, RobinsonMichael R, BejanianMarina, WirtaDavid L,

IOP lowering
Corneal adverse events

Both 10 and 15 µg bimatoprost implants effectively lowered intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), meeting the primary endpoint of noninferiority to timolol. The 10 µg implant had a lower risk of corneal adverse events and was favored over the 15 µg implant.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

18.

A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension.

Author: KatsanosAndreas, RivaIvano, BozkurtBanu, HollóGábor, QuarantaLuciano, OddoneFrancesco, IrkecMurat, DuttonGordon N, KonstasAnastasios G

Glaucoma management
OHT management

This review discusses the long-term safety and tolerability of topical prostaglandin analogues (PGAs) for managing glaucoma and ocular hypertension. While the short-term efficacy and safety of PGAs are well-established, long-term data are limited. This information is crucial for long-term therapy success, considering the lifelong nature of these conditions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

19.

Intracameral sustained release bimatoprost implants (Durysta).

Author: SirinekPortia E, LinMichael M

Improved medication adherence

Durysta, an FDA-approved sustained release intracameral treatment, has the potential to improve glaucoma care by decreasing medication adherence challenges.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

20.

Proposal of a simple grading system integrating cosmetic and tonometric aspects of prostaglandin-associated periorbitopathy.

Author: TanitoMasaki, IshidaAkiko, IchiokaSho, TakayanagiYuji, TsutsuiAika, ManabeKaoru, ShirakamiTomoki, SugiharaKazunobu, MatsuoMasato

Prostaglandin-associated periorbitopathy

This study evaluated the distribution of prostaglandin-associated periorbitopathy (PAP) among glaucoma/ocular hypertension subjects using a topical FP or EP2 receptor agonist. The results suggest that the Shimane University PAP Grading System (SU-PAP) is a simple and feasible grading system for PAP that can be used in real-world clinical situations.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

21.

Comparison of preserved bimatoprost 0.01% with preservative-free tafluprost: A randomised, investigator-masked, 3-month crossover, multicentre trial, SPORT II.

Author: LemmensSophie, RossettiLuca, OddoneFrancesco, Sunaric-MégevandGordana, HommerAnton, VandewalleEvelien, Francesca CordeiroMaria, McNaughtAndrew, MontesanoGiovanni, StalmansIngeborg

Reduced IOP

Bimatoprost, a prostaglandin analogue with a preservative (benzalkonium chloride), produced a statistically significant greater reduction in intraocular pressure (IOP) compared to tafluprost, a preservative-free prostaglandin analogue, with minimal to no difference in side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

22.

Granulomatous uveitis and choroidal detachment in a patient after topical treatment with Bimatoprost: A case report.

Author: MassimoLorusso, Micelli FerrariLuisa, Nikolopoulou GisottiEleni, ZitoRoberta, MicelliFerrariTommaso, AnnaFerretta, BordinoneMarco Antonio

Improved vision
Choroidal detachment
Glaucomatous uveitis

This case report describes an 80-year-old woman who developed bilateral glaucomatous uveitis and choroidal detachment in the left eye after topical bimatoprost administration. The uveitis and choroidal detachment resolved after discontinuation of bimatoprost and initiation of local steroid therapy.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

23.

Sustained-release drug delivery systems for the treatment of glaucoma.

Author: KesavNatasha P, YoungCara E Capitena, ErtelMonica K, SeiboldLeonard K, KahookMalik Y

Glaucoma treatment

This review focuses on novel sustained release drug delivery systems for glaucoma, a leading cause of blindness. The review discusses both currently available and future platforms, highlighting the potential to address limitations of traditional topical therapies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

24.

Effects of topical prostaglandin drops on angiogenesis in an in ovo chick chorioallantoic membrane model.

Author: SabanerMehmet Cem, DumanResat, VurmazAyhan, ErtekinTolga

Increased angiogenesis
Embryo hypoplasia

Topical prostaglandin drops increased angiogenesis in the chick CAM model in ovo, suggesting a potential role in promoting vascular growth.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.